Brief: Ackermans & Van Haaren Invests In Vico Therapeutics

Ackermans & Van Haaren NV

05/01/2024 06:35

Jan 5 (Reuters) - Ackermans & Van Haaren NV  ACKB.BR :
    * ACKERMANS & VAN HAAREN INVESTS IN VICO THERAPEUTICS
    * 54 MILLION EURO SERIES-B FUNDRAISING WILL ALLOW THE
COMPANY TO
CONTINUE THE CLINICAL DEVELOPMENT OF THIS IMPORTANT PROGRAM AND
SEVERAL OTHER PRECLINICAL ASO THERAPIES
    * THE COMPANY IS TRIALING ITS LEAD PROGRAM VO659 IN A
MULTICENTER
CLINICAL TRIAL ACROSS EUROPE IN SEVERAL TYPES OF SPINOCEREBELLAR
ATAXIA’S AND IN HUNTINGTON’S DISEASE, FOR WHICH IT BOTH RECEIVED
FDA’S ORPHAN DRUG DESIGNATION
    * AVH INITIALLY HOLDS 3,8% OF SHARES OF VICO THERAPEUTICS,
WITH
ITS SHAREHOLDING FURTHER INCREASING WHEN FULL AMOUNT  OF AVH’S
7,5 MILLION EURO COMMITMENT IS CALLED BY  COMPANY AFTER
ACHIEVING CERTAIN MILESTONES

Source text: http://tinyurl.com/3rvkup93
Further company coverage:  ACKB.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))